Journal
NATURE BIOTECHNOLOGY
Volume 20, Issue 2, Pages 143-148Publisher
NATURE AMERICA INC
DOI: 10.1038/nbt0202-143
Keywords
-
Categories
Funding
- NCI NIH HHS [CA-16520] Funding Source: Medline
- NIDDK NIH HHS [DK-19525, DK07748] Funding Source: Medline
Ask authors/readers for more resources
The ex vivo priming and expansion of human cytotoxic T lymphocytes (CTLs) has potential for use in immunotherapy applications for cancer and infectious diseases. To overcome the difficulty in obtaining sufficient numbers of CTLs, we have developed artificial antigen-presenting cells (aAPCs) expressing ligands for the T-cell receptor (TCR) and the CD28 and 4-1BB co-stimulatory surface molecules. These aAPCs reproducibly activate and rapidly expand polyclonal or antigen-specific CD8(+) T cells. The starting repertoire of CD8(+) T cells was preserved during culture. Furthermore, apoptosis of cultured CD8(+) T cells was diminished by this approach. This approach may have important therapeutic implications for adoptive immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available